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The CYP2C19 gene presents polymorphism affecting the pharmacokinetics of several drugs of clinical 
importance. The purpose of this study was to investigate the correlation between CYP2C19 genotype 
and metabolic phenotype in a group of 38 Brazilian volunteers, evaluating the phenotype prediction 
capacity of the genotyping procedure. For CYP2C19 phenotyping, omeprazole was used as the probe 
drug, using the hydroxylation metabolic ratio as the phenotypic indicator. Venous blood samples were 
drawn before and three hours after an oral administration of 20 mg omeprazole. The plasma concentrations 
of omeprazole and hydroxy-omeprazole were determined by high performance liquid chromatography. 
The genotyping assay was carried out using a Real-Time-PCR-based assay, identifying the alleles *1 
(completely functional), *2, *3 and *4 (null). The phenotyping procedure estimated the presence of 4 
poor, 34 extensive and 1 ultra-extensive metabolizer. The genotyping identified 4 poor, 23 extensive 
and 11 intensive metabolizers. The groups of volunteers classified according to the number of active 
alleles of CYP2C19 had significant differences in the metabolic ratios of omeprazole hydroxylation. 
However, volunteers exhibiting the same number of active alleles presented different phenotypes. 
Therefore, the phenotyping of CYP2C19 is a more promising alternative to dose individualization of 
CYP2C19 substrate drugs. 
Uniterms: Metabolic phenotyping. Metabolic genotyping. CYP2C19 gene.
O gene CYP2C19 apresenta polimorfismo genético, com impacto importante na farmacocinética 
de diversos fármacos de importância clínica. O objetivo deste estudo foi avaliar a correlação entre 
genótipo e fenótipo de CYP2C19 em um grupo de 38 voluntários brasileiros, avaliando a capacidade 
de predição do fenótipo a partir de testes de genotipagem. Para a fenotipagem, utilizou-se omeprazol 
(OME) como fármaco-sonda para CYP2C19, empregando sua razão metabólica de hidroxilação como 
indicador fenotípico. Amostras de sangue foram coletadas antes e três horas após a administração oral 
de 20mg do fármaco. As concentrações plasmáticas de OME e seu metabólito foram determinadas por 
cromatografia líquida de alta eficiência. A genotipagem de CYP2C19 foi realizada através de ensaio 
baseado na reação em cadeia da polimerase em tempo real, identificando os alelos *1 (completamente 
funcional),*2 e *3 (nulos). Pela fenotipagem foi possível estimar a presença de 3 metabolizadores lentos, 
34 rápidos e 1 ultra-rápido; enquanto pela genotipagem foi determinada a presença de 4 metabolizadores 
lentos, 23 rápidos e 11 intermediários. Os grupos de voluntários classificados de acordo com o número 
de alelos ativos apresentaram diferenças significativas entre as razões metabólicas de hidroxilação de 
omeprazol. Entretanto, indivíduos com o mesmo genótipo apresentaram fenótipos diferentes. Desta 
forma, a fenotipagem apresenta-se como alternativa mais promissora para a individualização das doses 
de fármacos substratos de CYP2C19.
Unitermos: Fenotipagem metabólica. Genotipagem metabólica. Gene CYP2C19
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INTRODUCTION
Drug kinetics presents considerably variation among 
individuals and a part of this variation can be credited to 
differences in expression and activity of cytochrome P450 
system (CYP). Among the clinically relevant CYP genes, 
CYP2C19 has particular importance. 
CYP2C19 gene presents genetic polymorphism, 
with significant effects on the disposition of several im-
portant drugs as amitriptyline, nortriptyline, diazepam, 
imipramine, propranolol and selective serotonine reuptake 
inhibitors (Linden, 2006). Besides the presence of the 
completely functional allele CYP2C19*1, the individual 
variability of CYP2C19 activity is associated to the presen-
ce of the null alleles CYP2C19*2 and CYP2C19*3, which 
has been described as responsible for about 87% of all poor 
metabolizers (PM) in Caucasian populations and 100% in 
Asians (Morais et al., 1994; Goldstein et al.,1997). Also, 
another alleles related to absence of CYP2C19 activity 
in vivo has been described, as CYP2C19*4, CYP2C19*5, 
CYP2C19*6, CYP2C19*7 and CYP2C19*8 (Human 
Cytochrome P450 allele Nomenclature Committee, 
2008). Recently, Sim and coworkers (2006) identified the 
CYP2C19*17 allele that is associated to increased activity 
of the CYP2C19 enzyme. 
One of the major objectives of clinical pharmacoge-
netics is the prediction of the individual metabolic activity, 
allowing proper dose adjustment. Then, individuals with 
reduced metabolic activity could receive lower drug doses, 
minimizing potential adverse effects, while patients with 
increased activity could receive higher doses, increasing 
the probability of a successful treatment. This prediction 
can be performed by genotyping of CYP and other genes 
related to drug metabolism, or alternatively trough the 
phenotyping of the enzymes by the administration of pro-
be drugs. Probe drugs are substances whose metabolism 
is well known, being metabolized mainly by the studied 
enzyme, and the rate of metabolite formation is used to 
evaluate the metabolic activity (Linden, Souto, 2005). 
CYP2C19 phenotyping is usually performed 
using omeprazole as probe drug, once the conversion of 
omeprazole (OME) to hydroxy-omeprazole (HOME) is 
mainly catalyzed by this enzyme, while the conversion of 
OME to omeprazole-sulphone (OMES) is dependent of 
CYP3A4 activity (Figure 1) (Streetman et al., 2000). The 
phenotypes are classified using metabolic ratios of OME 
hydroxylation, calculated with OME and HOME plasma 
concentrations 3 hours after a single oral administration of 
20 mg OME (Linden et al., 2007). This indicator is named 
metabolic ratio (MR) and usually presents a normal distri-
bution on tested populations (Tamminga et al., 2001). MR 
values below 0.12 are found in ultra-extensive metaboli-
zers (UE) and above 4.0 in poor metabolizers (PM), being 
classified as extensive metabolizers (EM) the individuals 
with intermediate values (González et al., 2003).
Before the incorporation of CYP2C19 genotyping 
to clinical practice, its phenotyping prediction capabili-
ty must be validated. Some recent works have shown a 
correlation between the MR of CYP2C19 with the geno-
type, but it is well known that the phenotype is affected 
by environmental and individual factors that cannot be 
predicted by genotyping procedures. As an example, 
previous studies have proposed tricyclic antidepressant 
dose adjustments based on CYP2C19 genotyping, with 
smaller doses recommended to PM patients (Kirchheiner 
et al., 2001; Kirchheiner et al., 2003). It must be pointed 
FIGURE 1 - Main metabolic routes of omeprazole. CYP2C19 catalyzes omeprazole hydroxylation forming 5-hydroxy-omeprazole, 
while CYP3A4 catalyzes the sulphonation reaction, leading to omeprazole-sulphone.
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out that the clinical application of these recommendations 
requires that to each determined genotype, a phenotype 
may be predicted with accuracy. 
Considering the inexistence of correlation studies 
among CYP2C19 genotype and phenotype in Brazilian 
population, the objective of this work was to evaluate the 
genotype-phenotype relation of this enzyme in a group 
of Brazilian volunteers, in order to know the phenotype 
predictive capability of the genotyping tests. 
MATERIALS AND METHODS 
Volunteer selection and sample collection 
The sampling protocol was approved by the Ethics 
Research Committee of Feevale University Center and 
an informed consent was signed by all volunteers parti-
cipating in the study. A group of 38 Caucasian volunteers 
(30 women and 8 men) participated in the study, all with 
age above 18, without history of liver or kidney disease, 
without history of hypersensitivity to drugs and that did 
not use any drug or herbal preparation two weeks before 
the collection of the samples. Main biodemographic data 
of the volunteers were: mean weight of 64.3 kg (range 51 
to 93 kg), mean body mass index of 23.1 (range 19.9 to 
31.1) and mean age of 27.4 years (range 21 to 43). 15 fe-
male volunteers used oral hormonal contraceptives during 
the study. The volunteers were oriented to remain fasted 
8 hours before sample collection. Venous blood samples 
were collected in vacuum tubes containing EDTA, either 
before and after the administration of the probe drug ome-
prazole. The sample collected before OME administration 
was used for genotyping. 
Determination of omeprazole and hydroxy-
omeprazole plasma levels 
Plasma concentrations of OME and HOME were 
determined by high-performance liquid chromatography 
(HPLC), as described by Linden et al. (2007). Briefly, to a 
1 mL plasma sample, Tris buffer pH 9.5 and internal stan-
dard sulpiride (IS) were added, followed by ethyl acetate 
extraction. After solvent evaporation, OME, HOME and IS 
were separated using a Shim-Pack RP-18e column (150 x 
4.6 mm, p.d. 5 µm), with a phosphate buffer pH 7.6-aceto-
nitrile (24:76, v/v) mobile phase. Flow rate was 1 mL/min 
and total run time was 15 min. Mean retention times were 
2.7 min for IS, 4.1 min for HOME and 11.6 min for OME. 
Detection (UV at 302 nm) was linear in the range of 25 
to 1000 ng/mL. The method has acceptable precision and 
accuracy, with a quantification limit of 25 ng/mL for both 
analytes. The chromatographic equipment was acquired 
from Shimadzu (Kyoto, Japan).
CYP2C19 phenotyping
The volunteers received single oral doses of 20 mg 
OME, together with 200 mL of water. Venous blood sam-
ples were drawn 3 hours after administration. Immedia-
tely after collection, samples were centrifuged at 2,000 g 
and plasma was transferred to polypropylene microtubes 
and stored at -20 °C until chromatographic analysis. The 
hydroxylation metabolic ratios were calculated using the 
values of OME and HOME concentration, and were defi-
ned as [OME]/[HOME]. Individuals with MR higher than 
4.0 were classified as PM, with MR lower than 0.12 were 
classified as UE and the group with intermediate values 
were classified as EM (González et al., 2003). The MR of 
the groups PM, UE and EM were compared by Kruskal-
Wallis test, with P = 0.001. SPSS version 11.5 was used 
for statistical calculations.
CYP2C19 genotyping
CYP2C19 genotyping was performed by a real-
time polymerase chain reaction assay (TaqMan® 
C_1329163_10, Applied Biosystems), according to the 
manufacturer’s instructions. The genotyping procedure 
was able to identify the alleles CYP2C19 *1, *2 e *3. For 
the determination of the number of active alleles, the *1 
allele was considered active and the alleles *2 e *3 were 
considered as inactive. Therefore, individuals with none 
active alleles were classified as PMg (genotypic poor 
metabolizer); individuals with 1 active allele were clas-
sified as IMg (genotypic intermediate metabolizer) and 
individuals with 2 active alleles were classified as EMg 
(genotypic extensive metabolizer). 
RESULTS AND DISCUSSION 
Table I presents the phenotypes predicted by the 
MR [OME]/[HOME] and by the genotyping for the 38 
volunteers. The phenotyping procedure allowed the iden-
tification of 4 PM (10.5 %), 33 EM (87 %) e 1 UE (2.5 
%). Alternatively, the genotyping identified 4 PMg (10.5 
%), 23 EMg (60.5 %) and 11 IMg (29 %). The frequencies 
of genotype-predicted phenotypes were similar to those 
found in previous studies with Caucasian populations 
(Goldstein et al., 1997; Sachse et al., 1997), although Xie 
et al. (1999) described a frequency of CYP2C19 PMg in 
the order of 2.8%. Naturally, the limited sample size of the 
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present study limits the comparison with wider previous 
investigations. 
The groups classified on their number of active 
alleles presented significant differences between the 
omeprazole hydroxylation metabolic ratios, the CYP2C19 
phenotypic indicator employed on this study, as presented 
in Table 2. Nevertheless, a clear superposition between 
[OME]/[HOME] values of the groups of number of active 
alleles was verified, with wider value dispersion in the 
PMg group (Figure 2, Table II). Probably, this superpo-
sition is related to the variability of alternative metabolic 
routes, especially by the biotransformation of omeprazole 
to omeprazole-sulphone catalyzed by CYP3A4 (Anders-
son et al., 1994).
Previous studies had determined threshold values 
for the classification of the PM and EM groups based on 
the calculation of antimodes of the normal distribution 
of MR. Considering that the small sampling size of the 
present study did not allow the calculation of antimodes, 
the use of previously determined values for CYP2C19 
phenotype classification based on omeprazole hydroxyla-
tion metabolic ratios (González et al., 2003) allowed the 
estimate of the presence of 1 UE (2.6%), 3 PM (7.9 %) e 
34 EM(89.5%) in the group of volunteers. 
During the development of this study, a genetic test 
for identification of the CYP2C19*17 allele, the only cur-
rently known that codifies a CYP2C19 isoform with incre-
ased activity, was not available. Taking into consideration 
the lack of reports of CYP2C19 induction by another drugs 
or environmental factors, it is probable that the presence 
of an UE volunteer among the volunteers could be due 
to presence of the *17 allele. Indeed, Sim and coworkers 
(2006) concluded that CYP2C19*17 homozygote indivi-
duals can present omeprazole area under the curve about 
35 to 40% smaller than CYP2C19*1 homozygote, after 
the administration of single oral doses. 
Considering that individuals with 1 CYP2C19 func-
tional allele usually have a EM phenotype, the number of 
PM and EM estimated either by phenotyping and geno-
typing are very similar. However, the genotyping did not 
allow the identification of 1 phenotypic UE in the group, 
considering that the genotyping procedure screened only 
the *1, *2 and *3 alleles. Also, one individual PMg had an 
omeprazole hydroxylation metabolic ratio compatible with 
the EM phenotype, as well as 2 individuals IMg presented 
a PM phenotype. Therefore, the genotyping procedure at 
the PMg group did not allowed an adequate prediction of 
the omeprazole hydroxylation activity of all participants 
of the study.
The results showed that, from a population view, 
there are statistically significant differences in the meta-
bolic activity of CYP2C19 among groups with different 
number of active alleles. However, in an individual basis, 
the CYP2C19 genotype cannot always predict accurately 
the metabolic activity. Phenotyping procedures using 
a probe drug as omeprazole allow the characterization 
of CYP2C19 activity at the moment of the test, being a 
more accurate measure of the extent of drug metabolism. 
Naturally, CYP2C19 activity is affected by a sort of en-
vironmental and individual factors, and the realization 
of phenotyping procedures every time a substrate of this 
enzyme is prescribed is unrealistic in clinical practice. 
Another alternative is the use of metabolic ratios obtained 
at routine therapeutic drug monitoring analyses, when the 
correlation of these rations and the phenotype of CYP2C19 
are well known (Van der Weide et al., 2005). Recent stu-
dies demonstrated the correlation of CYP2C19 phenotype 
with amitriptyline demethylation metabolic ratios, a re-
action also catalyzed by CYP2C19 (Linden et al., 2008). 
CONCLUSIONS
Groups of volunteers classified according to their 
number of CYP2C19 active alleles as PMg, IMg and EMg 
had significant differences on their omeprazole hydroxyla-
tion metabolic ratios. However, there was considerable 
variation on the metabolic ratios within groups, with 2 
PMg being classified as EM by phenotyping. Also, 2 IMg 
presented PM phenotype. CYP2C19 genotype did not 
present complete concordance with phenotypes. CYP2C19 
phenotyping is a promising tool to drug dose individua-
lization, once allow the determination of the metabolic 
activity at the desired moment. 
FIGURE 2 - Dispersion of omeprazole hydroxylation metabolic 
ratios with respect to the number of CYP2C19 active alleles.
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TABLE I - CYP2C19 phenotyping and genotyping data of volunteers
Volunteer Gender
[OME]/
[HOME]
Phenotype
Present 
alleles 
Number of active 
alleles
Genotype-predicted 
phenotype
1 M 0.05 UE *1/*1 2 EMg
2 F 0.54 EM *1/*1 2 EMg
3 F 0.61 EM *1/*1 2 EMg
4 F 0.80 EM *1/*1 2 EMg
5 F 0.80 EM *1/*1 2 EMg
6 M 0.90 EM *1/*1 2 EMg
7 F 0.90 EM *1/*1 2 EMg
8 F 1.10 EM *1/*1 2 EMg
9 F 1.17 EM *1/*1 2 EMg
10 F 1.22 EM *1/*1 2 EMg
11 F 1.24 EM *1/*1 2 EMg
12 M 1.24 EM *1/*1 2 EMg
13 F 1.25 EM *1/*2 1 IMg
14 M 1.25 EM *1/*1 2 EMg
15 M 1.30 EM *1/*1 2 EMg
16 F 1.34 EM *1/*1 2 EMg
17 F 1.40 EM *1/*2 1 IMg
18 F 1.51 EM *1/*1 2 EMg
19 M 1.55 EM *1/*1 2 EMg
20 F 1.64 EM *1/*1 2 EMg
21 M 1.65 EM *1/*1 2 EMg
22 F 1.69 EM *1/*2 1 IMg
23 F 1.70 EM *1/*2 1 IMg
24 F 1.72 EM *1/*1 2 EMg
25 F 1.97 EM *1/*2 1 IMg
26 M 2.06 EM *1/*2 1 IMg
27 F 2.12 EM *1/*1 2 EMg
28 F 2.12 EM *1/*2 1 IMg
29 F 2.27 EM *2/*2 0 PMg
30 F 2.41 EM *1/*1 2 EMg
31 F 2.45 EM *1/*1 2 EMg
32 F 2.77 EM *1/*2 1 IMg
33 F 2.83 EM *2/*2 0 PMg
34 F 3.03 EM *1/*2 1 IMg
35 F 3.97 PM *1/*2 1 IMg
36 F 5.44 PM *1/*2 1 IMg
37 F 6.62 PM *2/*2 0 PMg
38 F 9.83 PM *2/*2 0 PMg
OME, omeprazole; HOME, hydroxy-omeprazole; M, male; F, female; UE, ultra-extensive metabolizer; EM, extensive metabolizer; 
PM, poor metabolizer; IM, intermediate metabolizer. 
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